CClinicalTrials.gg
CompletedNCT03426150Updated Feb 8, 2018

Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks

A Phase 4 interventional study of CPP-ACP and Placebos in Dental Erosion, sponsored by Fujian Medical University. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-08.

Sponsored by Fujian Medical University · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

40 specimens were prepared from fresh-extracted human molars and further embedded using the acrylic resin. Specimens were randomly divided into 2 groups according to the treatment before in vivo erosion (n=20): CPP-ACP for 3 min (CPP-ACP group) and deionized water for 3 min (control group). 10 healthy volunteers were recruited and customized maxillary appliance containing 4 specimens (2 from CPP-ACP group and 2 from control group) was fabricated for each volunteer. Participants were instructed to drink 150 ml cola in 5 min using the gargling method after placing appliances intraorally for 2 h. The in vivo attacks were performed 4 X 5 min with 1-h interval daily over 7 d. The surface microhardness and surface microstructure of the specimens were evaluated at the baseline and after the treatment. The data were statistically analyzed using three-way ANOVA and post hoc tests. Data were considered statistically significant at a level of P \<0.05.

02

Conditions studied

  • Dental Erosion

Browse trials for

03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18 to 60 years of age and in good general health
  • Dental erosion and wear degree is 0-1

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases or oral mucosal disorders
  • Current orthodontic treatment
  • Pregnancy
  • Known allergies to the experimental drink
  • Had been given drugs which lead to dry oral more regularly within half a year
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    CPP-ACP

    Tooth mousse (GC, Japan) application on the specimen surface for 3 min.

    Drug: CPP-ACP

  • Placebo comparator
    Deionized water

    Deionized water application on the specimen surface for 3 min

    Drug: Placebos

Interventions

  • DrugCPP-ACP

    The surfaces of specimens were pretreated with CPP-ACP for 3 min

  • DrugPlacebos

    The surfaces of specimens were pretreated with deionized water for 3 min

05

What researchers measure

Primary outcomes

  1. Surface microhardness

    a Vickers microhardness tester with microscopic lens was used, with a 100 g load and 30-s dwell time. Three microhardness measurements were obtained on the top surface of each specimen.

    Time frame: baseline

  2. Surface microhardness

    a Vickers microhardness tester with microscopic lens was used, with a 100 g load and 30-s dwell time. Three microhardness measurements were obtained on the top surface of each specimen.

    Time frame: 7 days

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Yu H, Jiang NW, Ye XY, Zheng HY, Attin T, Cheng H. In situ effect of Tooth Mousse containing CPP-ACP on human enamel subjected to in vivo acid attacks. J Dent. 2018 Sep;76:40-45. doi: 10.1016/j.jdent.2018.05.021. Epub 2018 May 30. PubMed 29857075 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03426150
Lead sponsor
Fujian Medical University
Responsible party
Hao Yu (Department Head, Fujian Medical University) — Principal investigator
First posted
Feb 8, 2018
Start date
Dec 25, 2015
Primary completion
Oct 25, 2017
Completion
Feb 5, 2018
Last update
Feb 8, 2018

Study contacts

Hao Yu, DDS, PhD
principal investigator · School and Hospital of Stomatology, Fujian Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion